APA (7th ed.) Citation

The MMR-158 Study Group. (2019). A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: A phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

The MMR-158 Study Group. A Second Dose of a Measles-mumps-rubella Vaccine Administered to Healthy Four-to-six-year-old Children: A Phase III, Observer-blind, Randomized, Safety and Immunogenicity Study Comparing GSK MMR and MMR II with and Without DTaP-IPV and Varicella Vaccines Co-administration. Taylor & Francis Group, 2019.

MLA (9th ed.) Citation

The MMR-158 Study Group. A Second Dose of a Measles-mumps-rubella Vaccine Administered to Healthy Four-to-six-year-old Children: A Phase III, Observer-blind, Randomized, Safety and Immunogenicity Study Comparing GSK MMR and MMR II with and Without DTaP-IPV and Varicella Vaccines Co-administration. Taylor & Francis Group, 2019.